Weather Alert  

"Special Statement" The combination of increasing surface moisture, mainly clear skies and light to calm winds has resulted in the formation of fog across the area. Visibilities are generally ranging between 1/2 mile and 1 1/2 mile, although there is locally dense fog reducing visibilities to 1/4 mile. These conditions are expected to continue through the early morning. Motorists are advised to use caution while driving as rapid changes in visibility are possible. Reduce speed and use low beam headlights. -- Monday Oct.23 17,07:46 AM

A.G. Schneiderman Launches Antitrust Investigation into Mylan Pharmaceuticals, Maker of EpiPen

A preliminary review revealed that Mylan Pharmaceuticals may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems.

Print Email

Attorney General Eric T. Schneiderman: "No child’s life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker’s anti-competitive practices."

Photo by: Anissa Thompson, via Free Images.

New York, NY - September 6, 2016 - Today, Attorney General Eric T. Schneiderman announced his office has commenced an investigation into Mylan Pharmaceuticals Inc, the maker of EpiPens. A preliminary review by the Office of the Attorney General revealed that Mylan Pharmaceuticals may have inserted potentially anticompetitive terms into its EpiPen sales contracts with numerous local school systems. Mylan’s EpiPen is the predominant epinephrine autoinjector—a device and drug used in cases where an individual suffers a severe allergic reaction, which could otherwise lead to death—in the U.S. market.

“No child’s life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker’s anti-competitive practices,” Attorney General Eric T. Schneiderman said.  “If Mylan engaged in anti-competitive business practices, or violated antitrust laws with the intent and effect of limiting lower cost competition, we will hold them accountable. Allergy sufferers have enough concerns to worry about—the availability of life-saving medical treatment should not be one of them. I will bring the full resources of my office to this critical investigation.”